Strategic Calibration of API Manufacturing and Paragraph IV Milestones for Market Dominance
The global pharmaceutical sector is currently confronting a revenue transition of unprecedented scale, characterized by the convergence of the most […]
The global pharmaceutical sector is currently confronting a revenue transition of unprecedented scale, characterized by the convergence of the most […]
The pharmaceutical sector faces a revenue contraction of $236 billion through 2030 as blockbuster patents expire. This contraction is a
Win the Patent Cliff: The 30-Month CDMO Playbook Read Post »
The patent cliff is not a metaphor. It is a calendar event. A specific date — often visible years in
Defend the Moat: Extending Pharma Riches with Digital Health Read Post »
Introduction: Why Germany Matters More Than Ever For years, the narrative surrounding Germany was one of caution. A powerful but
The specialty pharmaceutical market is undergoing a structural realignment as high-value biologics and small molecules face their first wave of
Double Specialty Pharmacy Margins on Generic Day One Read Post »
The Patent Strategy That Keeps Failing Biologic drug developers have spent decades trying to own entire therapeutic concepts. Claim the
Stop Patenting the Goal: Why Specificity Is the Only Shield in Biologics Read Post »
Why Five Years Is the Only Number That Matters in Pharma When Pfizer’s patent on Lipitor expired in November 2011,
The Billion-Dollar Equation: How to win the five-year fight for patent exclusivity Read Post »
The Problem With Betting Everything on One Patent Every pharmaceutical brand team eventually confronts the same uncomfortable math. The active
The global biopharmaceutical industry is approaching a critical juncture as it faces a massive wave of patent expirations for some
Sign in or create a free account to read this DrugPatentWatch article